Traders bought shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading on Monday. $152.92 million flowed into the stock on the tick-up and $108.72 million flowed out of the stock on the tick-down, for a money net flow of $44.20 million into the stock. Of all companies tracked, Gilead Sciences had the 5th highest net in-flow for the day. Gilead Sciences traded down ($0.53) for the day and closed at $76.89

A number of brokerages recently commented on GILD. Barclays PLC reissued an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 28th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. RBC Capital Markets set a $105.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, August 11th. Morgan Stanley reduced their price objective on shares of Gilead Sciences from $107.00 to $103.00 and set an “equal weight” rating for the company in a research note on Thursday, May 26th. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 price objective for the company in a research note on Tuesday, July 26th. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $106.74.

The company has a market capitalization of $101.47 billion and a PE ratio of 6.75. The firm’s 50 day moving average is $81.16 and its 200-day moving average is $86.85.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.15 EPS. Analysts expect that Gilead Sciences Inc. will post $11.77 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Wednesday, September 14th.

In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total value of $9,444,960.00. Following the sale, the chief executive officer now owns 1,170,963 shares of the company’s stock, valued at $98,747,309.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 100,000 shares of the company’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the completion of the sale, the chairman now directly owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its stake in shares of Gilead Sciences by 43.3% in the fourth quarter. BNP Paribas Arbitrage SA now owns 3,213,246 shares of the biopharmaceutical company’s stock valued at $325,148,000 after buying an additional 970,463 shares during the period. Atlantic Trust Group LLC increased its stake in shares of Gilead Sciences by 40.4% in the fourth quarter. Atlantic Trust Group LLC now owns 182,527 shares of the biopharmaceutical company’s stock valued at $18,470,000 after buying an additional 52,554 shares during the period. Clifford Swan Investment Counsel LLC increased its stake in shares of Gilead Sciences by 13.0% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 156,708 shares of the biopharmaceutical company’s stock valued at $15,857,000 after buying an additional 18,030 shares during the period. Coho Partners Ltd. increased its stake in shares of Gilead Sciences by 2.0% in the fourth quarter. Coho Partners Ltd. now owns 704,635 shares of the biopharmaceutical company’s stock valued at $71,302,000 after buying an additional 14,145 shares during the period. Finally, Private Advisor Group LLC increased its stake in shares of Gilead Sciences by 7.9% in the fourth quarter. Private Advisor Group LLC now owns 88,902 shares of the biopharmaceutical company’s stock valued at $8,996,000 after buying an additional 6,498 shares during the period.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.